The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors

Pachocki, 2022, Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma, J. Neuroinflammation, 19, 276, 10.1186/s12974-022-02630-8 Hwang, 2018, IMMU-09. Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): A pediatric brain tumor consortium study (PBTC045), Neuro Oncol., 20, i100, 10.1093/neuonc/noy059.325 Persson, 2022, The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies, Neuro Oncol., 24, 1408, 10.1093/neuonc/noac117 Ausejo-Mauleon, 2023, TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory, Cancer Cell, 41, 1911, 10.1016/j.ccell.2023.09.001 Wolf, 2020, TIM3 comes of age as an inhibitory receptor, Nat. Rev. Immunol., 20, 173, 10.1038/s41577-019-0224-6 Qin, 2020, Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation, Front. Oncol., 10, 1288, 10.3389/fonc.2020.01288 Krysko, 2012, Immunogenic cell death and DAMPs in cancer therapy, Nat. Rev. Cancer, 12, 860, 10.1038/nrc3380 Xie, 2022, Research progress in inducing immunogenic cell death of tumor cells, Front. Immunol., 13, 10.3389/fimmu.2022.1017400 Baek, 2022, Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders, Front. Neurol., 13, 10.3389/fneur.2022.880814